EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma

BACKGROUND: Despite the remarkable breakthroughs achieved in the management of metastatic melanoma using immunotherapy and targeted therapies, long‐term clinical efficacy is often compromised due to dose‐limiting toxicity and innate or acquired resistance. Therefore, it is of vital importance to fur...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Guangtong, Zeng, Furong, He, Yi, Meng, Yu, Sun, Huiyan, Su, Juan, Zhao, Shuang, Cheng, Yan, Chen, Xiang, Yin, Mingzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858631/
https://www.ncbi.nlm.nih.gov/pubmed/35184394
http://dx.doi.org/10.1002/ctm2.722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858631/
https://www.ncbi.nlm.nih.gov/pubmed/35184394
http://dx.doi.org/10.1002/ctm2.722

Ejemplares similares